Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor

Journal of Controlled Release

Volumn 142, Issue 2, 2010, Pages 167-173

  Abu Lila, Amr S ^a   Doi, Yusuke ^a   Nakamura, Kazuya ^a   Ishida, Tatsuhiro ^a   Kiwada, Hiroshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Anticancer drug; Anticancer therapy; Oxaliplatin; PEG coated cationic liposomes; Sequential administration

Indexed keywords

ANTI-CANCER AGENTS; ANTI-CANCER THERAPIES; ANTI-TUMOR ACTIVITIES; ANTICANCER DRUG; CATIONIC LIPOSOMES; CYTOTOXIC EFFECTS; DEEP DIFFUSION; INTERSTITIAL SPACE; OXALIPLATIN; PRACTICAL IMPORTANCE; SEQUENTIAL INJECTION; SOLID TUMORS; THERAPEUTIC EFFICACY; TUMOR ACCUMULATION; TUMOR CELLS; TUMOR MODELS;

COMPLEXATION; DRUG THERAPY; ENDOTHELIAL CELLS; LIPOSOMES; PHOSPHOLIPIDS; POLYETHYLENE GLYCOLS;

TUMORS;

LIPOSOME; MACROGOL; OXALIPLATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG EFFICACY; LIPOSOMAL DELIVERY; LUNG CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; CATIONS; LIPOSOMES; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS;

EID: 76749093024     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.10.020     Document Type: Article

References (42)

1. Yuan F., Leunig M., Huang S.K., Berk D.A., Papahadjopoulos D., Jain R.K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 1994, 54:3352-3356.
2. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 1997, 26:71-90.
3. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. J. Control. Release 1998, 53:4967.
4. Karita M., Tsuchiya H., Kawahara M., Kasaoka S., Tomita K. The antitumor effect of liposome-encapsulated cisplatin on rat osteosarcoma and its enhancement by caffeine. Anticancer Res. 2008, 28:1449-1457.
5. Lammers T., Hennink W.E., Storm G. Tumour-targeted nanomedicines: principles and practice. Br. J. Cancer 2008, 99:392-397.
6. Hong M., Zhu S., Jiang Y., Tang G., Pei Y. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. J. Control. Release 2009, 133:96-102.
7. Zhao H., Wang J.C., Sun Q.S., Luo C.L., Zhang Q. RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer. J. Drug Target. 2009, 17:10-18.
8. Xiong X.B., Huang Y., Lu W.L., Zhang X., Zhang H., Nagai T., Zhang Q. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. J. Pharm. Sci. 2005, 94:1782-1793.
9. Hussain S., Pluckthun A., Allen T.M., Zangemeister-Wittke U. Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol. Cancer Ther. 2007, 6:3019-3027.
10. Sun W., Zou W., Huang G., Li A., Zhang N. Pharmacokinetics and targeting property of TFu-loaded liposomes with different sizes after intravenous and oral administration. J. Drug Target. 2008, 16:357-365.
11. Lee C.M., Tanaka T., Murai T., Kondo M., Kimura J., Su W., Kitagawa T., Ito T., Matsuda H., Miyasaka M. Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res. 2002, 62:4282-4288.
12. Morimoto K., Kondo M., Kawahara K., Ushijima H., Tomino Y., Miyajima M., Kimura J. Advances in targeting drug delivery to glomerular mesangial cells by long circulating cationic liposomes for the treatment of glomerulonephritis. Pharm. Res. 2007, 24:946-954.
13. Asai T., Miyazawa S., Maeda N., Hatanaka K., Katanasaka Y., Shimizu K., Shuto S., Oku N. Antineovascular therapy with angiogenic vessel-targeted polyethyleneglycol-shielded liposomal DPP-CNDAC. Can. Sci. 2008, 99:1029-1033.
14. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
15. Kim J.H., Kim Y.S., Kim S., Park J.H., Kim K., Choi K., Chung H., Jeong S.Y., Park R.W., Kim I.S., Kwon I.C. Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel. J. Control. Release 2006, 111:228-234.
16. Maeda H., Bharate G.Y., Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm. 2009, 71:409-419.
17. Abu-Lila A., Suzuki T., Doi Y., Ishida T., Kiwada H. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model. J. Control. Release 2009, 134:18-25.
18. Abu Lila A.S., Kizuki S., Doi Y., Suzuki T., Ishida T., Kiwada H. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model. J. Control. Release 2009, 137:8-14.
19. Bartlett G.R. Colorimetric assay methods for free and phosphorylated glyceric acids. J. Biol. Chem. 1959, 234:469-471.
20. Harashima H., Yamane C., Kume Y., Kiwada H. Kinetic analysis of AUC-dependent saturable clearance of liposomes: mathematical description of AUC dependency. J. Pharmacokinet. Biopharm. 1993, 21:299-308.
21. Arnould S., Guichard S., Hennebelle I., Cassar G., Bugat R., Canal P. Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line. Biochem. Pharmacol. 2002, 64:1215-1226.
22. Eriguchi M., Nonaka Y., Yanagie H., Yoshizaki I., Takeda Y., Sekiguchi M. A molecular biological study of anti-tumor mechanisms of an anti-cancer agent oxaliplatin against established human gastric cancer cell lines. Biomed. Pharmacother. 2003, 57:412-415.
23. Photos P.J., Bacakova L., Discher B., Bates F.S., Discher D.E. Polymer vesicles in vivo: correlations with PEG molecular weight. J. Control. Release 2003, 90:323-334.
24. Kawano T., Okuda T., Aoyagi H., Niidome T. Long circulation of intravenously administered plasmid DNA delivered with dendritic poly(l-lysine) in the blood flow. J. Control. Release 2004, 99:329-337.
25. Romberg B., Hennink W.E., Storm G. Sheddable coatings for long-circulating nanoparticles. Pharm. Res. 2008, 25:55-71.
26. Safra T., Muggia F., Jeffers S., Tsao-Wei D.D., Groshen S., Lyass O., Henderson R., Berry G., Gabizon A. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500mg/m2. Ann. Oncol. 2000, 11:1029-1033.
27. Krown S.E., Northfelt D.W., Osoba D., Stewart J.S. Use of liposomal anthracyclines in Kaposi's sarcoma. Semin. Oncol. 2004, 31:36-52.
28. Allen T.M., Mumbengegwi D.R., Charrois G.J. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin. Cancer Res. 2005, 11:3567-3573.
29. Pastorino F., Mumbengegwi D.R., Ribatti D., Ponzoni M., Allen T.M. Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin. J. Control. Release 2008, 126:85-94.
30. ElBayoumi T.A., Torchilin V.P. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin. Cancer Res. 2009, 15:1973-1980.
31. Shmeeda H., Mak L., Tzemach D., Astrahan P., Tarshish M., Gabizon A. Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors. Mol. Cancer Ther. 2006, 5:818-824.
32. Gabizon A., Horowitz A.T., Goren D., Tzemach D., Shmeeda H., Zalipsky S. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin. Cancer Res. 2003, 9:6551-6559.
33. Schiffelers R.M., Koning G.A., ten Hagen T.L., Fens M.H., Schraa A.J., Janssen A.P., Kok R.J., Molema G., Storm G. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Control. Release 2003, 91:115-122.
34. Nielsen U.B., Kirpotin D.B., Pickering E.M., Hong K., Park J.W., Refaat Shalaby M., Shao Y., Benz C.C., Marks J.D. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim. Biophys. Acta 2002, 1591:109-118.
35. Kobayashi T., Ishida T., Okada Y., Ise S., Harashima H., Kiwada H. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int. J. Pharm. 2007, 329:94-102.
36. Suzuki R., Takizawa T., Kuwata Y., Mutoh M., Ishiguro N., Utoguchi N., Shinohara A., Eriguchi M., Yanagie H., Maruyama K. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int. J. Pharm. 2008, 346:143-150.
37. Park J.W., Hong K., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., Shao Y., Nielsen U.B., Marks J.D., Moore D., Papahadjopoulos D., Benz C.C. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 2002, 8:1172-1181.
38. Eliaz R.E., Szoka F.C. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res. 2001, 61:2592-2601.
39. Lu Y., Yang J., Sega E. Issues related to targeted delivery of proteins and peptides. Aaps J. 2006, 8:E466-478.
40. Tredan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99:1441-1454.
41. Au J.L., Kumar R.R., Li D., Wientjes M.G. Kinetics of hallmark biochemical changes in paclitaxel-induced apoptosis. AAPS PharmSci 1999, 1:E8.
42. Au J.L., Jang S.H., Wientjes M.G. Clinical aspects of drug delivery to tumors. J. Control. Release 2002, 78:81-95.